Study of Milvexian for Stroke Prevention
This study investigates if a medicine called milvexian can help prevent strokes in people who have recently had a stroke or a specific kind of stroke warning called a Transient Ischemic Attack (TIA). A stroke happens when blood flow to the brain is blocked, causing brain damage. TIA is a short-term blockage with no lasting damage.
Key Points:
- The study lasts until a few days after the last dose of milvexian.
- Participants are required to start the study within 48 hours after their stroke or TIA.
- Women must not be pregnant or breastfeeding during the study.
To join, participants must meet certain conditions like having a low National Institute of Health Stroke Score (NIHSS), which measures the severity of a stroke, and be taking low-dose aspirin. People with certain health issues, such as previous brain bleeding or liver disease, cannot participate. It's important to know the study might involve risks, such as possible side effects from milvexian. Participants will be randomly assigned to take either milvexian or a placebo, which is a harmless pill that doesn't contain medicine, to see if milvexian works better.
How understandable was the trial content above?
Hard to understand
Easy to understand